When should a provider consider insulin human inhalation powder?

Journal of the American Academy of Physician Assistants

Volumn 29, Issue 5, 2016, Pages 16-18

  Mospan, Cortney M ^a   Leonard, Chelsea ^b   Alley, Kelli ^c  

^a EAST TENNESSEE STATE UNIVERSITY   (United States)

^b SAMFORD UNIVERSITY   (United States)

^c Bill Gatton College of Pharmacy   (United States)

Author keywords

Afrezza; diabetes; glucose control; insulin human inhalation powder; management; mealtime

Indexed keywords

ANTIDIABETIC AGENT; HUMAN INSULIN; INSULIN;

HUMAN; INHALATIONAL DRUG ADMINISTRATION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS;

ADMINISTRATION, INHALATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, REGULAR, HUMAN;

EID: 84977652927     PISSN: 15471896     EISSN: 08937400     Source Type: Journal    
DOI: 10.1097/01.JAA.0000482307.71186.01     Document Type: Article

References (7)

1. Afrezza prescribing information. Danbury, CT: MannKind Corp.; 2014. www.afrezza.com. Accessed February 17, 2016.
2. Afrezza. Lexicomp Online. http://online.lexi.com. Accessed February 17, 2016.
3. Davies MJ, Gagliardino JJ, Gray LJ, et al. Real-world factors affecting adherence to insulin therapy in patients with type 1 or type 2 diabetes mellitus: a systematic review. Diabet Med. 2013;30(5):512-524.
4. Heinemann L. The failure of exubera: are we beating a dead horse? J Diabetes Sci Technol. 2008;2(3):518-529.
5. Insulin aspart. Lexicomp Online. http://online.lexi.com. Accessed February 17, 2016.
6. Rosenstock J, Lorber DL, Gnudi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet. 2010;375(9733):2244-2253.
7. Insulin lispro. Lexicomp Online. http://online.lexi.com. Accessed February 17, 2016.